The abstract is read at the publisher; the summary is JClub's.
Carboplatin plus mirvetuximab soravtansine achieved an investigator-assessed objective response rate of 62.7% in recurrent platinum-sensitive ovarian cancer with folate receptor alpha (FRα) ≥50% expression.
- Why it matters: Platinum-sensitive ovarian cancer that recurs after prior platinum therapy needs more effective, tolerable options, especially for tumors expressing FRα and for patients previously exposed to PARP inhibitors.
- What they did: In a phase 2 single-arm trial, patients with recurrent FRα-expressing PSOC (≥25% of tumor cells with ≥2+ membrane intensity) received up to 6–8 cycles of carboplatin (AUC 5) plus MIRV (6 mg/kg AIBW) every 3 weeks, then single-agent MIRV.
- The result: Among 125 enrolled patients, ORR was 62.7% in the FRα ≥50% group and 62.4% in the overall population; most patients (n=101; 81%) continued MIRV, with median progression-free survival of 11.0 months for FRα ≥25%, while blurred vision (81%) and corneal events (74%) were common and pneumonitis occurred in 15.2% (including 2 fatal cases).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.